Australia Investing

Heritage Cannabis Holdings Corp. (CSE: CANN)(OTCQX: HERTF) (“Heritage” or the “Company”), today announced that it has executed a binding letter of intent (“LOI”) with IntelGenx Corp. (TSXV:IGX)(OTCQB:IGXT) (“IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, for the supply of filmstrip products containing CBD (“CBD Filmstrips”) for the Canadian and Australian markets.

Pursuant to the LOI and subject to entering into a Definitive Supply Agreement and the satisfaction of customary closing conditions, IntelGenx will manufacture filmstrips containing 10 mg of CBD using its VersaFilm® technology, for distribution and sale in Canada and Australia. In addition to receiving a manufacturing margin, IntelGenx will also receive a double-digit royalty on the gross margin based on product sales. Heritage will supply CBD material for IntelGenx’s filmstrip manufacture and supply in Canada and Australia on a non- and semi-exclusive basis, respectively. The LOI contemplates an option on future co-development of CBD and THC filmstrips using proprietary technology from both companies, under certain conditions.

Keep reading... Show less

Naturally Splendid Enterprises Ltd.  (TSXV: NSP) (OTCQB: NSPDF) (FSE: 50N) (“Naturally Splendid“) is pleased to announce they have signed an exclusive sales and distribution agreement for an extensive line of plant-based, meat alternative products, with one of Australia’s most popular plant-based manufacturers.

Naturally Splendid has come to terms with BettaLife Global Food Solutions of Australia for the exclusive sales and distribution rights for Canada, for a wide range of plant-based, meat alternative products. The Company has also been granted sales and distribution rights to access the United States market.

Keep reading... Show less

While interest in the psychedelic drug development business is beginning to pick up, one Australia-based advocate said it’s still very early in the country.

In an interview with the Investing News Network (INN) Peter Hunt, chairman of Mind Medicine Australia, shared his expectations for the development of the psychedelics industry in Australia as the sector begins to accelerate in North America.

Keep reading... Show less

The COVID-19 virus has affected Australian cannabis investment, but one corporate finance expert said there’s been an influx of money lately.

On Monday (June 22), during the first day of this year’s Prohibition Partners Live event, a panel of expert commentators discussed the adoption of cannabis stocks among investors and the larger marijuana business from an Australian perspective.

Keep reading... Show less

As the promise of psychedelic investments expands in North America, Australian investors are getting a tease on what could be coming down the line.

Last Friday (June 19), market participants were treated to presentations from three participants in the quickly growing psychedelic drug industry. The event was hosted by Melbourne-based investment and portfolio management firm Peak Asset Management.

Keep reading... Show less

Asterion Cannabis Inc. (“Asterion” or the “Company”), announces the appointment of Amy Stephenson, MBA, CFA, CPA, CMA, as Chief Investment Officer.

Amy Stephenson has the in-depth cannabis industry knowledge, experience and relationship collateral that allows her to provide relevant information, direction and leadership on optimal financing and public transaction strategies for cannabis companies during the infancy stage. Ms. Stephenson’s addition to the team brings Asterion, one of the most accomplished finance officers in the industry.

Keep reading... Show less